Report Code: TIPBT00002663 | No. of Pages: 193 | Category: Biotechnology | Status: Prebook
Biomarker, a biological molecule, is found in blood, tissues, or other body fluids that is a sign of a standard or abnormal process. A biomarker is used to see how well the body responds to a treatment for a disease or condition.
Market players are manufacturing a wide range of cancer biomarkers that offer maximum advantages and early diagnosis. In April 2021, Amgen launched the Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Moreover, in March 2022, Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
Furthermore, in December 2021, BioGenex launched three new primary immunohistochemistry (IHC) antibodies including CD8A, CD163, and CD56 for cancer diagnosis.
Additionally, recent advances in cancer immunotherapies have emerged in long-lasting clinical responses in patients. Cancer immunotherapies are rapidly replacing traditional treatment standards and expanding the therapeutic landscape for cancer patients. Researchers are focused on finding molecules in the blood that can signal the appearance of cancers. For the diagnosis of ovarian and prostate cancers, the cancer antigen (CA)125 and prostate-specific antigen (PSA) are used alongside other tests.
Additionally, advancements in high-throughput omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, accelerated the pace of biomarker discovery. Recently, the concept of identifying circulating tumor DNA through a liquid biopsy has moved to clinical reality. The Society for Immunotherapy of Cancer (SITC) reconvened biomarker for an Immune Task Force to review the state-of-the-art technologies, identify current hurdlers, and make recommendations for the field. Therefore, recent technological advancement has enabled many potential biomarkers and renewed in developing new biomarkers and drive the growth of cancer biomarkers market
|Market Size Value in||US$ 18,436.36 million in 2022|
|Market Size Value by||US$ 34,857.12 million by 2028|
|Growth rate||CAGR of 11.1% from 2022 to 2028|
|No. of Pages||193|
|No. of Tables||118|
|No. of Charts & Figures||78|
|Historical data available||Yes|
|Segments covered||Biomarker Type, Profiling Technology, Cancer Type, and Application|
|Free Sample Copy Available|
Emerging markets such as Asia Pacific are creating ample opportunities for significant market players to expand their business. Most of the major players focus on emerging countries such as India, China, and others owing to a large number of cancer patients and the growth of medical tourism in developing countries. Most of the emerging countries are preferred place for medical tourism.
As per the Australian Institute of Health and Welfare, 151,000 new cases of cancer are diagnosed in 2021. Furthermore, according to the Malaysia Healthcare Travel Council, in 2020, more than 2 million visited Malaysia for healthcare purposes doubling the medical tourism revenue to ~680 million. The low cost of surgeries and advanced technologies with less waiting time for procedures in the region are likely to boost the demand for cancer biomarkers.
Therefore, growing medical tourism in emerging countries and increasing cancer prevalence in Asia Pacific are anticipated to provide significant growth opportunities to the players operating in the cancer biomarkers market during the forecast period.
The cancer biomarkers market, based on biomarker type, is segmented into genetic biomarkers, protein biomarkers, and others. The protein biomarker segment held the largest share of the market in 2022 and is anticipated to register the highest growth rate during the forecast period.
Get more information on this report :Profiling Technology-Based Insights
The cancer biomarkers market, by profiling technology, is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. The omics technologies segment held the largest market share in 2022 and is anticipated to register the highest growth rate during 2022–2028.
The cancer biomarkers market, based on cancer type, is segmented into breast cancer, lung cancer, prostate cancer, leukemia, bladder cancer, and others. In 2022, the other segment held the largest share of the market. However, the lung cancer segment is expected to register the fastest growth rate in the coming years.
Based on application, the cancer biomarkers market is segmented into diagnostics, research and development, prognostics, and others. In 2022, the prognostics segment held the largest share of the market. Also, the same segment is anticipated to register the highest CAGR during the forecast period.
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the cancer biomarkers market. A few recent key market developments are listed below:
The List of Companies